← Search & browse all drugs

tebentafusp

L01XX75

Forms & Strengths

injection: 1000 mg/10 mL (100 mg/mL)

Adult Dosing

Loading dose: 20 mg, then 30 mg on day 8, then 15-30 mg weekly
Administered intravenously over 20 minutes

Pediatric Dosing

There is limited data on use in pediatric patients
Not recommended for patients under 18 years old

Indications

Treatment of HLA-A*02:01 positive adult patients with unresectable or metastatic uveal melanoma
Treatment of metastatic uveal melanoma

Mechanism of Action

Bispecific fusion protein that redirects T cells to target cancer cells expressing gp100
T cell activation occurs through CD3 receptor binding

Contraindications

No contraindications are listed, but caution advised in certain populations
History of severe hypersensitivity reaction to tebentafusp or its components

Adverse Reactions

Cytokine release syndrome (CRS)
Skin rash, pruritus, and fatigue
Nausea, diarrhea, and pyrexia

Drug Interactions

Immunosuppressive therapy may reduce efficacy of tebentafusp
Avoid live vaccines while on treatment

Curated Content: Needs Vetting Before Put to Clinical Use